Clinical trials: Recurrent Thymic Carcinoma
Advanced Thymic Carcinoma
Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy
Indication: Patients with advanced recurrent or metastatic thymic carcinoma. Phase IIa (China only):Approximately 6 patients. Phase IIb (China only):Approximately 54 patients.
- Trial name
- NCT07824505
- Testing
- lucitanib 15 mg QD, lucitanib 10 mg QD
- Where
- 16 sites in China
- Volunteers
- 74 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Graft Versus Host Disease, Leukemia
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases
RATIONALE: Umbilical cord blood transplantation may be able to replace cells destroyed by chemotherapy or radiation therapy. PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood transplantation in treating…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Thymic Carcinoma
- Trial name
- NCT00003662
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- 15 sites in United States
- Volunteers
- 90 people
- Sponsor
- Roswell Park Cancer Institute